ALFRY
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is involved in the ethical pharmaceuticals wholesaling business that offers diagnostic reagents and medical devices/equipment to hospitals, clinics, and dispensing pharmacies. The company also engages in self-medication products wholesaling business that offers over-the-counter drugs, including health foods, supplements, and other products to drug stores and pharmacies. In addition, it manufactures and markets active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, as well as undertakes contract manufacturing of pharmaceuticals. Further, the company's medical-related business includes its dispensing pharmacy and other medical-related activities. Alfresa Holdings Corporation was incorporated in 2003 and is based in Tokyo, Japan.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q4 | 54.33 | $754.6B | — |
| 2025 Q3 | 114.50 | $848.4B | — |
| 2025 Q2 | 36.00 | $785.1B | — |
| 2025 Q1 | 27.52 | $758.1B | $0 |
| 2025 Q4 | 9.10 | $698.7B | $0 |
| 2024 Q3 | 62.68 | $806.0B | $0 |
| 2024 Q2 | 51.55 | $734.0B | $0 |
| 2024 Q1 | 23.71 | $722.4B | $0 |